Incretins are metabolic hormones that are indeed stimulated from and secreted by specialised intestinal cells in response to food intake. These gastrointestinal peptides—principally glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—play a crucial role in regulating blood glucose levels by enhancing insulin secretion in a glucose-dependent manner. GLP-1 is produced by enteroendocrine L-cells, predominantly in the distal ileum and colon, whilst GIP is secreted by K-cells in the duodenum and proximal jejunum. Understanding how incretins are stimulated from intestinal cells has proven clinically significant, particularly in the development of incretin-based therapies for type 2 diabetes and obesity management.

What Are Incretins and Where Are They Produced?

Incretins are a group of metabolic hormones that play a crucial role in regulating blood glucose levels following food intake. These gastrointestinal peptides are indeed stimulated from and secreted by specialised intestinal cells in response to nutrient ingestion. The term 'incretin' derives from their ability to enhance insulin secretion in a glucose-dependent manner, meaning they promote insulin release only when blood glucose levels are elevated.

The two principal incretins in human physiology are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), formerly known as gastric inhibitory polypeptide. GLP-1 is predominantly produced by enteroendocrine L-cells, which are distributed throughout the intestinal mucosa but are most abundant in the distal ileum and colon. In contrast, GIP is secreted primarily by K-cells located in the duodenum and proximal jejunum of the small intestine.

These enteroendocrine cells function as nutrient sensors, detecting the presence of food components in the intestinal lumen and responding by releasing incretins into the bloodstream. Native GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which has important implications for therapeutic strategies. This gut-pancreas axis represents an elegant physiological mechanism whereby the digestive system communicates with the pancreas to prepare for glucose absorption. The incretin effect accounts for around half of total insulin secretion following oral glucose intake in healthy individuals, highlighting the substantial contribution of these intestinal hormones to postprandial glucose homeostasis.

Understanding incretin physiology has proven clinically significant, particularly in the development of novel therapeutic approaches for type 2 diabetes mellitus and, more recently, obesity management. NICE guidance (NG28) and the British National Formulary (BNF) provide UK-specific recommendations on incretin-based therapies.

How Intestinal Cells Release Incretins After Eating

The process of incretin secretion from intestinal cells is a sophisticated response to nutrient detection that begins within minutes of food consumption. When food enters the gastrointestinal tract, various nutrients—including carbohydrates, proteins, and fats—interact with specialised receptors on the surface of enteroendocrine cells. These cells possess nutrient-sensing mechanisms that detect specific dietary components and trigger hormone release accordingly.

Carbohydrates stimulate incretin secretion through multiple pathways. Glucose and other sugars are detected primarily by sodium-glucose co-transporter 1 (SGLT1) on enteroendocrine cells, which is the dominant glucose sensor for L-cells. The role of glucose transporter 2 (GLUT2) in this process remains under investigation. Additionally, sweet taste receptors (T1R2/T1R3) on these cells may sense glucose and artificial sweeteners, though evidence from human studies is inconsistent and the clinical relevance of this pathway requires further clarification. Proteins and amino acids also potently stimulate incretin secretion, with certain amino acids such as glutamine and phenylalanine being particularly effective triggers, though the magnitude of effect varies.

Dietary fats represent another important stimulus for incretin release, particularly for GLP-1. Free fatty acids interact with G-protein coupled receptors (GPR40, GPR120) on L-cells, promoting hormone secretion. The length and saturation of fatty acid chains influence the magnitude of this response.

The temporal pattern of incretin release is biphasic: an early phase occurs within 10–15 minutes of eating, likely triggered by neural and hormonal signals (including vagal nerve activity) even before nutrients reach the distal intestine, followed by a sustained phase as nutrients directly contact enteroendocrine cells throughout the small and large intestine. This coordinated response ensures appropriate insulin secretion matches the rate of nutrient absorption, thereby maintaining glycaemic stability. These mechanistic insights are largely derived from preclinical and ex vivo human cell models, with variable translation to clinical effects.

The Role of GLP-1 and GIP in Blood Sugar Control

GLP-1 and GIP exert complementary yet distinct effects on glucose homeostasis, working in concert to regulate postprandial blood glucose levels. Both hormones bind to specific G-protein coupled receptors on pancreatic beta cells, stimulating insulin secretion in a glucose-dependent manner. This glucose dependency is a critical safety feature: when blood glucose levels are normal or low, incretin-mediated insulin secretion diminishes, substantially reducing the risk of hypoglycaemia compared to some other glucose-lowering mechanisms.

GLP-1 demonstrates multiple beneficial actions beyond insulin secretion. It suppresses glucagon release from pancreatic alpha cells, thereby reducing hepatic glucose production when it is not needed. GLP-1 also slows gastric emptying, which moderates the rate at which nutrients enter the small intestine and are absorbed into the bloodstream. Furthermore, GLP-1 acts on the central nervous system to promote satiety and reduce appetite, contributing to potential weight loss—an effect that has been exploited therapeutically. In animal studies, GLP-1 has shown potential to preserve beta cell mass and function, though the extent of this effect in humans remains under investigation.

GIP primarily enhances glucose-stimulated insulin secretion. In individuals with type 2 diabetes, the insulinotropic effect of GIP is substantially reduced, whereas the effect of GLP-1 is relatively preserved. GIP may also have effects on fat metabolism, though its role in promoting lipid storage in adipose tissue in humans is uncertain and requires further investigation.

Together, these incretins account for the 'incretin effect'—the observation that oral glucose administration produces a greater insulin response than intravenous glucose delivery at equivalent blood glucose concentrations. In individuals with type 2 diabetes, this incretin effect is markedly reduced, contributing to postprandial hyperglycaemia and representing a key therapeutic target.

Factors That Stimulate Incretin Secretion

Multiple physiological and dietary factors influence the magnitude and duration of incretin secretion from intestinal cells. Understanding these factors provides insight into both normal physiology and potential therapeutic interventions.

Nutrient composition is the primary determinant of incretin release. As previously mentioned, carbohydrates, proteins, and fats all stimulate secretion, but their relative potency differs. Mixed meals containing all three macronutrients typically produce the most robust incretin response. The influence of glycaemic index and load of carbohydrates on the pattern of GLP-1 release is not entirely consistent across studies, though some evidence suggests that slowly absorbed carbohydrates may produce more sustained secretion.

Bile acids have emerged as important regulators of incretin secretion, particularly GLP-1. These molecules, released into the intestine during fat digestion, activate the G-protein coupled bile acid receptor TGR5 on L-cells, stimulating hormone release. The role of the farnesoid X receptor (FXR) is more complex and context-dependent. This mechanism may partly explain the metabolic improvements observed following bariatric surgery, which alters bile acid circulation.

The gut microbiome appears to modulate incretin secretion through production of short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate. These bacterial metabolites, produced through fermentation of dietary fibre, can stimulate GLP-1 release via specific receptors (FFAR2/GPR43 and FFAR3/GPR41) on enteroendocrine cells. This represents a potential mechanism linking dietary fibre intake with improved glycaemic control.

Neural and hormonal signals also influence incretin secretion. Vagal nerve activity, triggered by food ingestion, can stimulate incretin release even before nutrients reach the distal intestine. Other gastrointestinal hormones, including gastrin-releasing peptide, may modulate incretin secretion in a paracrine fashion. Physical factors such as intestinal distension and the rate of gastric emptying indirectly affect incretin levels by controlling nutrient delivery to enteroendocrine cells.

Clinical Significance of Incretins in Diabetes Treatment

The discovery that the incretin effect is substantially impaired in type 2 diabetes has led to the development of incretin-based therapies, which now represent a cornerstone of modern diabetes management. These medicines work by either mimicking or enhancing the action of endogenous incretins, thereby improving glycaemic control whilst offering additional metabolic benefits.

GLP-1 receptor agonists (such as exenatide, liraglutide, semaglutide, and dulaglutide) are synthetic analogues or modified versions of human GLP-1 that resist degradation by DPP-4. These agents are administered by subcutaneous injection (ranging from twice daily to once weekly, depending on the formulation) or, in the case of oral semaglutide (Rybelsus), as a daily tablet taken on an empty stomach. They effectively lower HbA1c by approximately 1.0–1.5 percentage points (roughly 11–16 mmol/mol) on average. NICE guidance (NG28) recommends considering GLP-1 receptor agonists as part of dual or triple therapy after metformin, particularly when weight loss would benefit the individual or when oral therapies are insufficient or not tolerated. Continuation criteria typically require demonstration of a clinically meaningful HbA1c reduction (for example, at least 11 mmol/mol or approximately 1 percentage point) and weight loss (at least 3% of body weight where applicable) at 6 months. Several GLP-1 receptor agonists have demonstrated cardiovascular benefits in outcome trials, reducing the risk of major adverse cardiovascular events in people with established cardiovascular disease.

DPP-4 inhibitors (such as sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin) work by blocking the enzyme that degrades endogenous GLP-1 and GIP, thereby prolonging their action. These oral medicines are generally well-tolerated and produce modest HbA1c reductions of approximately 0.5–0.8 percentage points (roughly 5–9 mmol/mol). They are weight-neutral and carry minimal hypoglycaemia risk when used as monotherapy or with metformin.

Common adverse effects of GLP-1 receptor agonists include gastrointestinal symptoms—particularly nausea, vomiting, and diarrhoea—which typically diminish with continued use. Patients should be advised to start with low doses and titrate gradually. Severe gastrointestinal symptoms may lead to dehydration and acute kidney injury; patients should maintain adequate fluid intake and seek medical advice if symptoms are persistent or severe. Other important cautions include an increased risk of gallbladder disease (cholelithiasis and cholecystitis) and, particularly with rapid HbA1c reduction (notably observed with semaglutide), worsening of diabetic retinopathy in individuals with pre-existing retinopathy. Rare but serious adverse effects include pancreatitis—patients should contact their GP urgently if they experience severe, persistent abdominal pain—and, potentially, thyroid C-cell tumours (observed in rodent studies; relevance to humans remains uncertain). DPP-4 inhibitors carry class warnings for pancreatitis, severe arthralgia, and bullous pemphigoid; certain agents (saxagliptin and alogliptin) have been associated with an increased risk of heart failure in some individuals and should be used with caution in those with heart failure.

Recent developments include dual GIP/GLP-1 receptor agonists such as tirzepatide, which is authorised by the MHRA for type 2 diabetes and harnesses the complementary effects of both incretins, producing superior glycaemic control and weight loss compared to selective GLP-1 agonists. NICE Technology Appraisals provide agent-specific NHS recommendations. The therapeutic landscape continues to evolve, with incretin-based therapies increasingly recognised not merely as glucose-lowering agents but as medicines offering broader cardiometabolic benefits.

Patients and healthcare professionals are encouraged to report suspected adverse drug reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Further information on dosing, cautions, and interactions is available in the BNF and individual Summary of Product Characteristics (SmPC) documents via the electronic Medicines Compendium (eMC) and NHS medicines pages.

Frequently Asked Questions